

# SUPPLEMENTARY PROSPECTUS

Little Green Pharma Ltd  
ACN 615 586 215



---

THIS IS A SUPPLEMENTARY PROSPECTUS TO THE PROSPECTUS LODGED WITH ASIC ON 19 DECEMBER 2019 AND MUST BE READ TOGETHER WITH THAT PROSPECTUS.

THIS IS AN IMPORTANT DOCUMENT REQUIRING YOUR IMMEDIATE ATTENTION AND SHOULD BE READ IN ITS ENTIRETY. IF YOU ARE IN DOUBT ABOUT WHAT TO DO, YOU SHOULD CONSULT YOUR STOCKBROKER, ACCOUNTANT, SOLICITOR, OR OTHER PROFESSIONAL ADVISOR.

AN INVESTMENT IN THE SECURITIES OFFERED BY THIS PROSPECTUS SHOULD BE CONSIDERED HIGHLY SPECULATIVE IN NATURE.

---

## 1. IMPORTANT INFORMATION

This is a supplementary prospectus (**Supplementary Prospectus**) intended to be read with the prospectus dated 19 December 2019 (**Prospectus**), issued by Little Green Pharma Ltd ACN 615 586 215 (**Company**).

This Supplementary Prospectus dated 9 January 2020 was lodged with the ASIC on that date. ASIC and its officers take no responsibility for the contents of this Supplementary Prospectus.

Other than as set out below, all details in relation to the Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus have the same meaning in this Supplementary Prospectus. If there is a conflict between the Prospectus and this Supplementary Prospectus, this Supplementary Prospectus will prevail.

This Supplementary Prospectus will be issued with the Prospectus as an electronic prospectus and may be accessed on a website hosted by the Share Registry at <https://lgpoffer.thereachagency.com>

This is an important document and should be read in its entirety. If you do not understand it you should consult your professional advisers without delay.

## 2. SUPPLEMENTARY INFORMATION

The purpose of this Supplementary Prospectus is to make the following revisions to the Prospectus.

## 3. LETTER FROM THE CHAIRMAN

The Letter from the Chairman is deleted and replaced with the following:

9 January 2020

Dear Investor

On behalf of the Board of Directors I am pleased to invite you to become a shareholder of Little Green Pharma Ltd (**Little Green Pharma**, **LGP** or the **Company**).

LGP was founded in 2016 with the aim of improving the quality of life for a child debilitated by seizures through the use of a patented small-particle formulation and to take advantage of opportunities relating to the emerging medicinal cannabis industry in Australia and in certain international jurisdictions.

Since then, LGP has invested significantly into product development, sales and marketing and cultivation capabilities with the aim of becoming a leading Australian medicinal cannabis company. LGP produces locally grown product in final dose form that has been used by more than 1,400 patients in Australia, with over 4,500 bottles of medicinal cannabis oil sold.

---

This Supplementary Prospectus is intended to be read with the prospectus lodged 19 December 2019 issued by Little Green Pharma Ltd (ACN 615 586 215).

The Board considers that LGP is strongly positioned to capture value from opportunities relating to the emerging medicinal cannabis industry in Australia and internationally. LGP has achieved several key milestones that effectively position the Company to execute its growth strategy:

- **First mover advantage and barriers to competition:** LGP was the first Australian company to achieve production of a locally-grown medicinal cannabis product for patient use. LGP has a track record of nearly two years of successful cannabis cultivation and is continuing its stability testing which is currently for 24 months in cold storage conditions (2-8°C) and twelve months at ambient conditions (below 25°C).
- **Accessible, proprietary-branded product range:** LGP currently offers three LGP-branded medicinal cannabis oil products in the Australian market and is proposing to launch additional products in the near term.
- **Nationwide patient uptake:** Following the launch of LGP's first medicinal cannabis product in August 2018, more than 1,400 patients in Australia have used LGP products.
- **Highly scalable production with planned expansion:** LGP is currently expanding its cultivation facility to have capacity to produce sufficient cannabis flower to manufacture more than 110,000 bottles of medicinal cannabis oil per annum.
- **Fully licenced business:** LGP, together with its exclusive Manufacturing Partner and distribution partners, holds all the necessary licences and permits to operate a vertically integrated medicinal cannabis business from cultivation to distribution.
- **TGA GMP-certified manufacturing facility:** LGP has an exclusive agreement for manufacturing services at a TGA GMP-certified manufacturing facility, which is a prerequisite for Australian medicinal cannabis producers to sell medicinal cannabis products into Australia and overseas.
- **Export distribution:** LGP has non-binding supply arrangements with distributors in Germany for the supply of LGP-branded and white-labelled products at a premium to Australian pricing and has received proof of concept conditional purchase orders for LGP products in Canada and New Zealand.
- **Education programmes:** LGP has developed, and is a sponsor of, the Green Choices portal, aimed at the education of physicians and patients to support patient access to medicinal cannabis.
- **Growing intellectual property portfolio:** LGP has patented a small particle formulation with the aim of improving the delivery of medicinal cannabis. The Company continues to undertake research and development activities in respect to alternative medicinal cannabis delivery systems with the aim of identifying additional patentable innovations.

LGP is accelerating its growth strategy by expanding operations in Australia and internationally with the aim of increasing market share and realising economies of scale. In the near term, LGP will seek to expand its cannabis cultivation operations and its manufacture of medicinal cannabis products for patient use in Australia. Over the longer term, LGP intends to progress various clinical development programmes focusing on the creation of high-value products.

The Offer is being made to provide funds to undertake sales and marketing activities supporting the Company's international expansion and export activities; to increase the market awareness and outreach of the Company; to undertake research and development activities in respect to its medicinal cannabis products and delivery technologies; to offer training and education relating to medicinal cannabis, LGP and its products; to implement new systems; and to provide working capital.

To fund the growth plan, LGP is seeking to raise a minimum of \$5,000,000 and a maximum of \$10,000,000 through the issue of up to 22,222,222 Shares at a price of \$0.45 per Share pursuant to the Offer.

The Offer is an important next step in the evolution of the Company and the Board believes this funding accelerates the growth strategy to capture value in a dynamic global market. The Offer provides an opportunity for incoming investors to share in our exciting future. This Prospectus contains detailed information about the Offer, financial position, operations, management team and expansion plans of LGP.

Section 6 includes a description of the key risks associated with an investment in LGP, including (but not limited to) risks in respect to LGP's ability to maintain, vary and obtain new medicinal cannabis licences and permits, the Office of Drug Control (ODC) revoking LGP's existing licences if the ODC determines that the Company, certain of the Company's personnel and/or the Company's major shareholder is not a "fit and proper" person, the Department of Health (Cth) refusing to renew LGP's existing import or export licences or grant the requisite permits, LGP's offshore distribution activities, the Manufacturing Partner failing to meet their commitments and obligations to LGP, and the expansion and scaling of LGP's operations. Section 6 should be read in detail. I encourage you to read the Prospectus carefully and in its entirety before making your investment decision and, if required, consult with your accountant, stockbroker, lawyer, or other independent professional adviser.

On behalf of the Directors, I invite you to consider this opportunity to invest in LGP and look forward to welcoming you as a Shareholder.

Yours sincerely,



**Mr Michael David Lynch-Bell**  
Independent Non-Executive Chairman  
Little Green Pharma Ltd

---

This Supplementary Prospectus is intended to be read with the prospectus lodged 19 December 2019 issued by Little Green Pharma Ltd (ACN 615 586 215).

## 4. INVESTMENT OVERVIEW

The second bullet point in the topic “*What is the Clinical Development programme for the Company?*” is deleted and replaced with the following:

**ARISE:** ARISE is a supercritical anti-solvent extraction technology which increases the surface area of particles of active pharmaceutical ingredients with the potential to increase absorption of drugs by the body. LGP holds an exclusive licence to exploit the ARISE technology in connection with medicinal cannabis and has entered into a research and development agreement with Curtin University to explore new formulations of medicinal cannabis that utilise the ARISE technology.

## 5. COMPANY OVERVIEW

(a) Figure 2 “LGP Business Model Overview” in Section 3.3 of the Prospectus is deleted and replaced with the following:



1. If the Manufacturing Partner wishes to terminate the agreement for convenience it can only do so after 22 November 2023 and with 12 months’ notice, meaning the earliest date on which the manufacturing agreement could be terminated is 23 November 2024.
2. Subject to the Company receiving the Maximum Subscription under the Offer.

(b) The first paragraph in Section 3.8(b) of the Prospectus is deleted and replaced with the following:

As at the date of this Prospectus, LGP is progressing a novel product development and formulation project with Curtin University in Western Australia. Curtin University owns a patented atomised rapid injection for solvent extraction (ARISE) technology that generates particles of active pharmaceutical ingredients that are more readily absorbed by the body. The Company has entered into a research and development agreement with Curtin University pursuant to which the parties will seek to explore new formulations that utilise the ARISE technology, including buccal drug delivery systems and fast-dissolving oral formulations capable of delivering micro-dose cannabinoid therapy.

(c) The table in Section 3.10 of the Prospectus is deleted and replaced with the following:

Approval	Description	Issuer	Renewal Date
<b>Medicinal Cannabis Licence</b>	Authorises the cultivation (the growing of cannabis plants) and production	ODC	28 May 2020
<b>Medicinal Cannabis Permit</b>	Establish the quantities of cannabis mother plants and flowering plants LGP is permitted to cultivate and produce		28 May 2020
			28 May 2020
<b>Indent Licence</b>	Allows on-sale of cannabis products to holders of appropriate wholesale and retail licences	State Health (WA)	9 April 2020
<b>Schedule 9 Licence</b>	Allows supply of Schedule 9 cannabis products		8 August 2020
<b>Licence to Import</b>	Authorises the importation of cannabis products subject to obtaining permit for specific import quantities	ODC	31 December 2020
<b>Licence to Export</b>	Authorises the export of cannabis products subject to obtaining permit for specific export quantities		31 December 2020
<b>ARTG (Export only) listing: 10:10 LGP Classic</b>	Lists specific cannabis products for export on the ARTG	Therapeutic Goods Administration	NA
<b>ARTG (Export only) listing: T10:C10 LGP Classic</b>			
<b>ARTG (Export only) listing: 20:5 LGP Classic</b>			
<b>ARTG (Export only) listing: T20:C5 LGP Classic</b>			

## 6. CONSENTS

Each of the Directors has given his or her written consent to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn his or her consent.

## 7. APPLICATION FOR SHARES

The Exposure Period for the Offer has expired and the Offer is now open. Applications for Shares under the Offer should be made using the Application Forms provided with the Prospectus (as supplemented by this Supplementary Prospectus). The Application Forms contain detailed instructions on how they are to be completed.


The Directors believe that the changes in this Supplementary Prospectus are not materially adverse from the point of view of an investor. Accordingly, no action needs to be taken if you have already applied for Shares under the Offer.

## 8. GENERAL

Other than as provided in this Supplementary Prospectus, all other information contained in the Prospectus remains unchanged.

## 9. DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.



Mr Michael David Lynch-Bell  
Independent Non-Executive Chairman

Dated: 9 January 2020

This Supplementary Prospectus is intended to be read with the prospectus lodged 19 December 2019 issued by Little Green Pharma Ltd (ACN 615 586 215).